Search: onr:"swepub:oai:DiVA.org:liu-71380" >
Combination of pegy...
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
-
- Simonsson, Bengt (author)
- Uppsala universitet,Medicin,Hematologi,Uppsala University
-
- Gedde-Dahl, Tobias (author)
- Oslo University Hospital
-
- Markevärn, Berit (author)
- Umeå universitet,Onkologi,Umea University
-
show more...
-
- Remes, Kari (author)
- Turku University Hospital
-
- Stentoft, Jesper (author)
- Aarhus University Hospital
-
- Almqvist, Anders (author)
- Vaasa Central Hospital
-
- Bjoreman, Mats (author)
- University Hospital, Hematol Unit, Orebro, Sweden
-
- Flogegard, Max (author)
- Falun Central Hospital
-
- Koskenvesa, Perttu (author)
- University of Helsinki
-
- Lindblom, Anders (author)
- Malmö University Hospital
-
- Malm, Claes (author)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US
-
- Mustjoki, Satu (author)
- University of Helsinki
-
- Myhr-Eriksson, Kristina (author)
- Luleå Centralral Hospital
-
- Ohm, Lotta (author)
- Karolinska Hospital
-
- Rasanen, Anu (author)
- Kymenlaakso Central Hospital
-
- Sinisalo, Marjatta (author)
- Tampere University Hospital
-
- Själander, Anders (author)
- Umeå universitet,Medicin,Sundsvall Central Hospital
-
- Strömberg, Ulla (author)
- Uppsala universitet,Medicin,Hematologi,Uppsala University
-
- Weiss Bjerrum, Ole (author)
- University of Copenhagen
-
- Ehrencrona, Hans (author)
- Uppsala universitet,Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine,Institutionen för immunologi, genetik och patologi,Uppsala University
-
- Gruber, Franz (author)
- University of Tromso
-
- Kairisto, Veli (author)
- Turku University
-
- Olsson, Karin (author)
- Reg Oncol Centre, Uppsala
-
- Sandin, Fredrik (author)
- Reg Oncol Centre, Uppsala
-
- Nagler, Arnon (author)
- Chaim Sheba Medical Centre
-
- Lanng Nielsen, Johan (author)
- Aarhus University Hospital
-
- Hjorth-Hansen, Henrik (author)
- St Olavs Hospital Trondheim
-
- Porkka, Kimmo (author)
- University of Helsinki
-
show less...
-
(creator_code:org_t)
- Washington D.C. American Society of Hematology, 2011
- 2011
- English.
-
In: Blood. - Washington D.C. : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 118:12, s. 3228-3235
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Biologic and clinical observations suggest that combining imatinib with IFN-alpha may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and in imatinib-induced complete hematologic remission either to receive a combination of pegylated IFN-alpha 2b (Peg-IFN-alpha 2b) 50 mu g weekly and imatinib 400 mg daily (n = 56) or to receive imatinib 400 mg daily monotherapy (n = 56). The primary endpoint was the major molecular response (MMR) rate at 12 months after randomization. In both arms, 4 patients (7%) discontinued imatinib treatment (1 because of blastic transformation in imatinib arm). In addition, in the combination arm, 34 patients (61%) discontinued Peg-IFN-alpha 2b, most because of toxicity. The MMR rate at 12 months was significantly higher in the imatinib plus Peg-IFN-alpha 2b arm (82%) compared with the imatinib monotherapy arm (54%; intention-to-treat, P = .002). The MMR rate increased with the duration of Peg-IFN-alpha 2b treatment (andlt; 12-week MMR rate 67%, andgt; 12-week MMR rate 91%). Thus, the addition of even relatively short periods of Peg-IFN-alpha 2b to imatinib markedly increased the MMR rate at 12 months of therapy. Lower doses of Peg-IFN-alpha 2b may enhance tolerability while retaining efficacy and could be considered in future protocols with curative intent.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Simonsson, Bengt
-
Gedde-Dahl, Tobi ...
-
Markevärn, Berit
-
Remes, Kari
-
Stentoft, Jesper
-
Almqvist, Anders
-
show more...
-
Bjoreman, Mats
-
Flogegard, Max
-
Koskenvesa, Pert ...
-
Lindblom, Anders
-
Malm, Claes
-
Mustjoki, Satu
-
Myhr-Eriksson, K ...
-
Ohm, Lotta
-
Rasanen, Anu
-
Sinisalo, Marjat ...
-
Själander, Ander ...
-
Strömberg, Ulla
-
Weiss Bjerrum, O ...
-
Ehrencrona, Hans
-
Gruber, Franz
-
Kairisto, Veli
-
Olsson, Karin
-
Sandin, Fredrik
-
Nagler, Arnon
-
Lanng Nielsen, J ...
-
Hjorth-Hansen, H ...
-
Porkka, Kimmo
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood
- By the university
-
Linköping University
-
Lund University
-
Umeå University
-
Uppsala University